Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

The US Food and Drug Administration (FDA) has accepted for priority review Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Bullous Pemphigoid Market Outlook 2025-2035: The 7 major Bullous Pemphigoid market reached a value of USD 287.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,618.1 ...

The Mavericks' mid-season rash of injuries continued on Saturday with the loss of backup big man Maxi Kleber. The Associated Press Maxi Kleber joins Dereck Lively and Dwight Powell among the Mavs ...

There are numerous reasons you might feel pain in your foot. Injury, poor alignment of the foot bones, or deterioration of the protective cushioning around the bones are a few of the issues that can ...

The $149.99 slide — which comes in orange, red, beige, black and blue — is tailored to the wearer’s foot. According to the site, the customer is asked to scan their feet with their phone ...